Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07003464 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

Name: Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study — clinical trial record (NCT07003464)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorThe First Hospital of Jilin University

Started2025-06-15

View on ClinicalTrials.gov ↗

The First Hospital of Jilin University

86 trials monitored

See 2 trials at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Chronic Lymphocytic Leukemia (CLL)

451 trials monitored

See 32 trials at risk

This is a single arm, open label, national multicenter clinical study included patients with chronic lymphocytic leukemia (CLL). The treatment combines three medications: Zanubrutinib , Obinutuzumab and Bendamustine . Together, these drugs aim to achieve deep remission (no detectable cancer cells) and allow a shorter treatment duration compared to lifelong therapies.

Trial Details

NCT Number	NCT07003464
Lead Sponsor	The First Hospital of Jilin University
Conditions	Chronic Lymphocytic Leukemia
Enrollment	30 participants
Start Date	2025-06-15
Primary Completion	2027-06-01 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-06-04